A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.

被引：2

作者：

Krishnan, Amrita Y.

Patel, Krina K.

Hari, Parameswaran

Jagannath, Sundar

Niesvizky, Ruben

Silbermann, Rebecca Wang

Berg, Deborah T.

Li, Qing

Allikmets, Kristina

Stockerl-Goldstein, Keith

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[4] Mt Sinai Med Ctr, New York, NY 10029 USA

[5] New York Presbyterian Hosp, Cornell Campus, New York, NY USA

[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[7] Takeda Pharmaceut Int, Cambridge, MA USA

[8] Takeda Pharmaceut, Cambridge, MA USA

[9] Washington Univ, St Louis, MO 63110 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8539

引用

页数：2